Seviteronel racemate, also known as VT-464 racemate, is primarily investigated for its potential in treating hormone-dependent cancers, particularly prostate cancer. It functions as an androgen biosynthesis inhibitor, targeting the CYP17A1 enzyme, which plays a critical role in the production of androgens. By inhibiting this enzyme, it reduces the levels of androgens that fuel the growth of prostate cancer cells. This mechanism makes it a promising candidate for patients with castration-resistant prostate cancer (CRPC), where traditional hormone therapies are no longer effective. Additionally, its ability to selectively inhibit CYP17A1 without significantly affecting cortisol production may offer a favorable safety profile compared to other treatments in this class. Research is ongoing to explore its efficacy, safety, and potential applications in other androgen-driven conditions.